The high CAM6/CAM5/E-cad and E-cad/ZEB1 mRNA expressions were significantly associated with poorer relapse-free survival in the Her2+ER−PR−, but not in the Her2−ER+PR+ and Her2−ER−PR−, breast cancer patient cohorts (Figs 9D and S8A). Here, ERBB2 is linked to breast cancer.